Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study - Ren, Zhenggang; Xu, Jianming; Bai, Yuxian; Xu, Aibing; Cang, Shundong; Du, Chengyou; Li, Qiu; Lu, Yinying; Chen, Yajin; Guo, Yabing; Chen, Zhendong; Liu, Baorui; et al. (The lancet oncology, 2021)
Keywords: Adverse events; Angiogenesis; Antibodies; Bevacizumab; Biological products; Blood clots; Cancer therapies; Consent; Dosage; Drug withdrawal; FDA approval; Hematology, Oncology, and Palliative Medicine; Hemorrhage; Hepatitis B; Hepatocellular carcinoma; Hyperkalemia; Infections; Inhibitor drugs; Intravenous administration; Liver cancer; Lung diseases; Metastases; Metastasis; Monoclonal antibodies; Patients; PD-1 protein; Population studies; Radiation therapy; Safety; Solid tumors; Survival; Targeted cancer therapy; Toxicity; Translation; α-Fetoprotein; United States--US; China